Article info

Download PDFPDF

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer

Authors

  1. Correspondence to Dr Robert Pirker; Robert.Pirker{at}meduniwien.ac.at
View Full Text

Citation

Pirker R, Filipits M
From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer

Publication history

  • Received May 23, 2019
  • Accepted May 24, 2019
  • First published September 8, 2019.
Online issue publication 
September 08, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.